Validation of Proteomic Analyses for Allergic Asthma and Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

133 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to verify and validate the intrinsic diagnostic value in terms of sensitivity and specificity of proteomic profiles determined during a pre-study for discriminating between allergy related asthma and allergy related rhinitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity

NCT00584051

Asthma Allergic Rhinitis

TERMINATED

VALIDATION OF THE CHAPTER "ALLERGIES AND HYPERSENSITIVITY" OF THE INTERNATIONAL DISEASE CLASSIFICATION (CIM)

NCT03213808

ALLERGIC OR HYPERSENSITIVITY

UNKNOWN

Evaluation of Nasal Inflammatory Biomarkers

NCT03450031

Seasonal Allergic Rhinitis

COMPLETED NA

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing

NCT00813748

Allergic Asthma

COMPLETED

Nasal Allergen Challenge in Rhinitic Subjects

NCT01286129

Asthma Allergic Rhinitis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rhinitis, Allergic Asthma, Allergic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients

Allergy patients, asthma and rhinitis

Classification as "asthmatic" or "rhinitis only" via proteomic analysis

Intervention Type BIOLOGICAL

Proteomic profiles are established for each patient using plasma and serum samples

Classification as "asthmatic" or "rhinitis only" according to a metacholine test

Intervention Type BIOLOGICAL

A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Classification as "asthmatic" or "rhinitis only" via proteomic analysis

Proteomic profiles are established for each patient using plasma and serum samples

Intervention Type BIOLOGICAL

Classification as "asthmatic" or "rhinitis only" according to a metacholine test

A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* signed consent
* never-smokers or non-smoking for at least 2 years + \< 5 packs per year
* capable of understanding the study
* patient is affiliated with a social security system
* positive skin tests (at least one for Montpellier region pneumoallergens)
* treated with nasal or inhaled corticoids, leucotriene receptor antagonists, anti-IgE, Theophylline, anti-histamines, sodium cromoglycate, beta-blockers, benzodiazépine, oral corticoids: all these treatments must be interrupted for at least 72 hours

Exclusion Criteria

* Co-morbidities: none; no co-morbidities are accepted
* dental infections (any) during the 3 months preceding the study
* suspected alcoholism or drug abuse
* chronic viral infection (hepatitis, HIV)
* patient under guardianship

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No